CR10486A - Tratamiento de tumores en pacientes pediatricos con antagonistas del receptor del factor de crecimiento epidermico - Google Patents
Tratamiento de tumores en pacientes pediatricos con antagonistas del receptor del factor de crecimiento epidermicoInfo
- Publication number
- CR10486A CR10486A CR10486A CR10486A CR10486A CR 10486 A CR10486 A CR 10486A CR 10486 A CR10486 A CR 10486A CR 10486 A CR10486 A CR 10486A CR 10486 A CR10486 A CR 10486A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antagonists
- receptor
- growth factor
- epidermal growth
- pediatric patients
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 title 1
- 101800003838 Epidermal growth factor Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229940116977 epidermal growth factor Drugs 0.000 title 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 229940122558 EGFR antagonist Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 208000012191 childhood neoplasm Diseases 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La combinacion de metodos de terapia para tratar tumores pediatricos mediante la administracion de un antagonista del EGFR y un agente quimioterapeutico. Los metodos incluyen tratar tumores pediatricos refractarios.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83348706P | 2006-07-27 | 2006-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR10486A true CR10486A (es) | 2009-02-23 |
Family
ID=38982334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR10486A CR10486A (es) | 2006-07-27 | 2008-12-09 | Tratamiento de tumores en pacientes pediatricos con antagonistas del receptor del factor de crecimiento epidermico |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2043688A4 (es) |
| JP (1) | JP2009544736A (es) |
| KR (1) | KR20090033841A (es) |
| CN (1) | CN101484186A (es) |
| AU (1) | AU2007279261A1 (es) |
| BR (1) | BRPI0712368A2 (es) |
| CA (1) | CA2654911A1 (es) |
| CR (1) | CR10486A (es) |
| EA (1) | EA200870603A1 (es) |
| EC (1) | ECSP089011A (es) |
| MX (1) | MX2008016187A (es) |
| NO (1) | NO20085182L (es) |
| TN (1) | TNSN08512A1 (es) |
| WO (1) | WO2008014386A2 (es) |
| ZA (1) | ZA200810600B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021011750A (es) | 2019-03-27 | 2021-12-10 | Nat Res Council Canada | Anticuerpos anti-egfrviii y fragmentos de union a antigenos de los mismos. |
-
2007
- 2007-07-26 JP JP2009522001A patent/JP2009544736A/ja not_active Withdrawn
- 2007-07-26 AU AU2007279261A patent/AU2007279261A1/en not_active Abandoned
- 2007-07-26 EP EP07813400A patent/EP2043688A4/en not_active Withdrawn
- 2007-07-26 MX MX2008016187A patent/MX2008016187A/es not_active Application Discontinuation
- 2007-07-26 CN CNA2007800249991A patent/CN101484186A/zh active Pending
- 2007-07-26 WO PCT/US2007/074448 patent/WO2008014386A2/en not_active Ceased
- 2007-07-26 EA EA200870603A patent/EA200870603A1/ru unknown
- 2007-07-26 KR KR1020087031606A patent/KR20090033841A/ko not_active Withdrawn
- 2007-07-26 CA CA002654911A patent/CA2654911A1/en not_active Abandoned
- 2007-07-26 BR BRPI0712368-0A patent/BRPI0712368A2/pt not_active Application Discontinuation
-
2008
- 2008-12-09 CR CR10486A patent/CR10486A/es not_active Application Discontinuation
- 2008-12-11 NO NO20085182A patent/NO20085182L/no not_active Application Discontinuation
- 2008-12-11 TN TNP2008000512A patent/TNSN08512A1/en unknown
- 2008-12-15 ZA ZA200810600A patent/ZA200810600B/xx unknown
- 2008-12-24 EC EC2008009011A patent/ECSP089011A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20085182L (no) | 2009-04-24 |
| ECSP089011A (es) | 2009-01-30 |
| EP2043688A2 (en) | 2009-04-08 |
| KR20090033841A (ko) | 2009-04-06 |
| WO2008014386A3 (en) | 2008-07-03 |
| TNSN08512A1 (en) | 2010-04-14 |
| CA2654911A1 (en) | 2008-01-30 |
| EP2043688A4 (en) | 2009-11-11 |
| JP2009544736A (ja) | 2009-12-17 |
| EA200870603A1 (ru) | 2009-06-30 |
| WO2008014386A2 (en) | 2008-01-31 |
| MX2008016187A (es) | 2009-01-20 |
| AU2007279261A1 (en) | 2008-01-31 |
| ZA200810600B (en) | 2009-11-25 |
| BRPI0712368A2 (pt) | 2012-06-05 |
| CN101484186A (zh) | 2009-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502155A1 (en) | Myostatin antagonism in human subjects | |
| MX381475B (es) | Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. | |
| CY1116344T1 (el) | Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| BRPI0908635B8 (pt) | composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica | |
| IN2014DN11099A (es) | ||
| MX2010006363A (es) | Sistemas, aparatos, metodos y procedimientos para el tratamiento no invasivo de tejido usando energia de microondas. | |
| CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
| MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
| MX344355B (es) | Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal. | |
| EA201490194A1 (ru) | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака | |
| MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
| AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
| NZ587706A (en) | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use | |
| JOP20130236B1 (ar) | تركيبات صيدلانية تشتمل على مثبط b-raf ومثبط egfr ومثبط اختياري لــpi3k alpha | |
| EA201201464A1 (ru) | Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний | |
| NZ712184A (en) | Combination therapy comprising a b-raf inhibitor and a second inhibitor | |
| MX2020009773A (es) | Terapia de combinacion. | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| MX2020009911A (es) | Usos de inhibiores de dpp iv. | |
| MX2016008072A (es) | Compuestos al receptor-3 del factor de crecimiento del fibroplasto (fgfr3) y metodos de tratamiento. | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |